Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; sodium hydroxide; hydrochloric acid - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; sodium hydroxide; hydrochloric acid - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vancomycin hydrochloride, quantity: 500 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin is an antibiotic used for treating potentially life-threatening infections caused by gram-positive organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: - desferrixamine is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions. long term therapy with desferrioxamine slows accumulation of hepatic iron and retards or eliminated progression of hepatic fibrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cytarabine -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cytarabine -